Adults with type 2 diabetes who took 100 mg of aspirin daily experienced fewer first heart attacks and other serious vascular events compared with those given a placebo, according to the ASCEND trial, one of the largest randomized studies to test aspirin for primary prevention in this population. The trial enrolled participants with diabetes who had no prior cardiovascular disease, and its results have shaped an ongoing debate about whether the bleeding risks of daily aspirin outweigh the heart-protection benefits, especially as newer diabetes drugs and widespread statin use have already driven down cardiac event rates.
Shifting risk calculus for aspirin in diabetes
The question facing clinicians and patients is not whether aspirin prevents heart attacks in people with diabetes. The ASCEND trial, a randomized, placebo-controlled study published in The New England Journal of Medicine, confirmed that it does. The harder question is whether the size of that benefit still justifies the well-documented increase in major bleeding events, particularly gastrointestinal hemorrhage.
When the American Diabetes Association, American Heart Association, and American College of Cardiology Foundation issued their joint position statement on aspirin for primary prevention, they recommended a dose range of 75 to 162 mg per day for adults with diabetes who meet certain cardiovascular risk thresholds. That recommendation, however, was shaped by an era when fewer patients were on potent statins, SGLT2 inhibitors, or GLP-1 receptor agonists. Each of those therapies independently lowers cardiovascular risk. As background event rates fall, the absolute number of heart attacks prevented by adding aspirin shrinks, while the absolute number of bleeding episodes stays roughly constant. That arithmetic can flip the net benefit calculation, turning a once-clear recommendation into a closer call.
The practical result: a person with type 2 diabetes whose cholesterol, blood pressure, and blood sugar are well controlled with modern medications may gain less from daily aspirin than trial participants enrolled a decade or more ago. Clinicians now have to weigh each patient’s residual cardiovascular risk against their individual bleeding profile before reaching for the aspirin bottle.
ASCEND and POPADAD trial findings on 100 mg aspirin
ASCEND remains the single most informative trial on this question. It tested 100 mg of aspirin daily against placebo in adults with diabetes who had no evident cardiovascular disease. Its primary endpoints included serious vascular events such as myocardial infarction, stroke, and transient ischemic attack. The trial found that aspirin reduced these events, but the benefit was partly offset by an increase in major bleeding, producing what the investigators described as a balance between vascular protection and hemorrhagic harm.
An earlier trial, POPADAD, published in The BMJ, examined the same 100 mg daily dose in a different but related population: patients with diabetes and asymptomatic peripheral arterial disease, identified by ankle-brachial index measurement. POPADAD used a factorial design that also tested antioxidants alongside aspirin. Its cardiovascular outcome data added to the evidence base but did not show a clear net benefit from aspirin in that subgroup, raising early questions about whether diabetes alone is sufficient justification for routine aspirin therapy.
Together, these two trials illustrate a consistent pattern. Aspirin at 100 mg daily can prevent a first heart attack in people with diabetes, but the margin of benefit depends heavily on how high the patient’s baseline risk is. When that baseline risk is already reduced by other treatments, the net gain from aspirin narrows. The ADA/AHA/ACCF position statement acknowledged this tension by recommending that benefits be weighed against bleeding on an individual basis, rather than applying a blanket prescription to all adults with diabetes.
Unanswered questions about long-term net benefit
Several gaps in the evidence remain open. Neither ASCEND nor POPADAD published granular subgroup analyses stratified by the type or intensity of concurrent glucose-lowering therapy. That means clinicians cannot yet determine, from trial data alone, whether a patient on an SGLT2 inhibitor or GLP-1 agonist derives the same relative benefit from aspirin as a patient managed with metformin alone. Duration of diabetes is another variable that could shift the risk-benefit equation, since longer disease duration is associated with higher cardiovascular risk, but individual participant-level data broken down by diabetes duration from these trials have not been made publicly available in the sources reviewed.
The bleeding side of the ledger also needs sharper definition. Full primary endpoint tables and detailed bleeding event counts from the complete ASCEND dataset are not available beyond the published summary. Without those granular numbers, it is difficult to model exactly which patient profiles tip from net benefit to net harm.
A related open question is whether the 75 to 162 mg per day dosing range endorsed in the joint position statement should be narrowed further. The two major trials both tested 100 mg, and there is limited head-to-head evidence comparing different low-dose aspirin regimens in diabetes-specific populations. Whether 75 mg would preserve the cardiovascular benefit while reducing bleeding, or whether 162 mg would provide any incremental protection at the cost of more hemorrhage, remains uncertain in the absence of direct comparative data.
Another issue is duration of therapy. ASCEND followed participants for several years, but type 2 diabetes is a lifelong condition, and cumulative bleeding risk may rise over decades. Gastrointestinal mucosa becomes more fragile with age, and comorbidities such as chronic kidney disease or liver dysfunction can amplify bleeding tendencies. Long-term concomitant use of other medications that affect coagulation, such as nonsteroidal anti-inflammatory drugs or anticoagulants, can further complicate the risk profile. Yet primary prevention trials generally do not extend far enough to map these long-horizon trade-offs in detail.
Real-world adherence adds another layer of uncertainty. In clinical practice, many patients do not take aspirin consistently over time, either because of minor side effects like dyspepsia or because they question the benefit once they hear about bleeding risks. Intermittent use could blunt cardiovascular protection without meaningfully reducing the chance of a major bleed, but large randomized data specifically addressing adherence patterns in diabetes populations are lacking.
Implications for everyday decision-making
Given these uncertainties, most experts now emphasize individualized assessment rather than automatic prescribing. For a middle-aged adult with type 2 diabetes, multiple additional risk factors, and no history of bleeding, a 100 mg aspirin regimen similar to that used in ASCEND may still be reasonable after a careful discussion of pros and cons. By contrast, for an older patient with well-controlled risk factors, a prior peptic ulcer, or concurrent anticoagulant use, even a modest reduction in first heart attacks may not justify the added chance of a serious hemorrhage.
Shared decision-making is central to this process. Patients often value avoiding a disabling stroke or heart attack more than they fear a gastrointestinal bleed, especially if they perceive bleeding as treatable and nonfatal. Others may prioritize minimizing any risk of hospitalization or invasive procedures, tilting them away from aspirin. Clinicians can use the available trial data to frame the conversation in terms of absolute numbers: how many heart attacks might be prevented per thousand similar patients, and how many major bleeds might be caused, recognizing that these figures are approximate and may not fully reflect modern background therapy.
Guideline writers face a parallel challenge. As more cardioprotective diabetes medications become standard, the incremental value of aspirin may continue to erode, particularly in lower-risk individuals. Future updates to position statements will likely need to incorporate evolving event rates and, ideally, more detailed subgroup analyses when they become available. Until then, the best approach is cautious, personalized use of low-dose aspirin, grounded in the current evidence but flexible enough to adapt as new data emerge.
For now, ASCEND and POPADAD suggest that 100 mg of aspirin daily can still play a role in primary prevention for selected adults with type 2 diabetes, but not as a one-size-fits-all solution. The balance between preventing first cardiovascular events and provoking serious bleeding is narrow and highly sensitive to each patient’s overall risk profile. Thoughtful, case-by-case decisions, rather than broad population-wide mandates, are likely to yield the most favorable outcomes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
